Efficiency and tolerability of drug AEvit in complex treatment of patients with atopic dermatitis

Abstract

Objective — to evaluate the effectiveness and tolerability of drug AEvit in the complex treatment of patients with atopic dermatitis (AD).Materials and methods. We observed 100 patients with AD, who were randomized into the main (50 patients) and control (50 patients) groups. Demographic and anamnestic data were collected from all patients, clinical signs of AD on the SCORAD (Severity scoring of atopic dermatitis: Consensus Report of the European Task Force on Аtopic Dermatitis) scale were evaluated, general clinical biochemical studies were performed. Inclusion criteria were: male and female gender, age from 18 to 70 years, diagnosis of AD in the stage of exacerbation established on the basis of the criteria of Hanifin and Rajka1; moderate or severe degree of the disease (30—70 points on the SCORAD scale); affected area < 30 % of the body surface. Patients underwent standard therapy. Patients of the main group additionally took AEvit, 1 capsule per day after meals for 30 days. Statistical processing of the obtained results was carried out with the use of methods of biometric analysis implemented in the packages of licensed programs Excel 2003 and Statistica 6.1 (StatSoft Inc., serial number AGAR909E415822FA).Results and discussion. Analysis of the anamnestic data allowed establishing the duration of the disease: up to 1 year — in 27 patients, 1—5 years — in 45 patients, 5—10 years — in 21 patients, more than 10 years — in 7 patients. There were 35 (35 %) men and 65 (65 %) women among the examined patients with AD. The duration of the disease according to the anamnestic history was 52.8 years in the main group, and 4.18 — in the control group. After the course of treatment, 28 (56 %) patients of the main group and 19 (38 %) patients of the control group achieved complete clinical remission of the disease. In all other cases, a significant reduction in the SCORAD index was achieved.Conclusions. There was a statistically significant decrease in the severity of the symptoms of the disease in both groups, but it was much more pronounced in the group of patients who used AEvit in the complex treatment.